Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
MaxCyte, Inc. MXCT
$3.81
+$0.08 (2.01%)
На 18:04, 12 мая 2023
+188.71%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
485370210.00000000
-
week52high
7.50
-
week52low
3.36
-
Revenue
44261500
-
P/E TTM
-25
-
Beta
0.70305300
-
EPS
-0.22000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 20:00
Описание компании
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| BTIG | Buy | Buy | 15 авг 2022 г. |
| William Blair | Outperform | 24 авг 2021 г. | |
| Stifel | Buy | 24 авг 2021 г. | |
| Stephens & Co. | Overweight | 24 авг 2021 г. | |
| Cowen & Co. | Outperform | 24 авг 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Doerfler Douglas | D | 385080 | 10665 | 02 февр 2023 г. |
| Doerfler Douglas | D | 333197 | 10665 | 02 февр 2023 г. |
| Doerfler Douglas | A | 343862 | 10665 | 02 февр 2023 г. |
| Ross Thomas M. | D | 72135 | 11575 | 02 февр 2023 г. |
| Ross Thomas M. | D | 0 | 11575 | 02 февр 2023 г. |
| Ross Thomas M. | A | 11575 | 11575 | 02 февр 2023 г. |
| Doerfler Douglas | D | 395745 | 19335 | 01 февр 2023 г. |
| Doerfler Douglas | D | 333197 | 19335 | 01 февр 2023 г. |
| Doerfler Douglas | A | 352532 | 19335 | 01 февр 2023 г. |
| Ross Thomas M. | D | 83710 | 15090 | 01 февр 2023 г. |
Новостная лента
MaxCyte, Inc. (MXCT) Loses 18.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks Investment Research
21 дек 2022 г. в 11:17
MaxCyte, Inc. (MXCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
7 Hot Stocks to Book Profits In Before 2023
InvestorPlace
19 дек 2022 г. в 12:55
Although a new year tends to bring feelings of optimism, when it comes to the current market dynamics, it's time to consider hot stocks to book profits in before 2023 arrives. At first, circumstances appeared favorable, with CNN reporting on Dec. 13 that inflation cooled more than expected.
MaxCyte, Inc. (MXCT) Moves to Buy: Rationale Behind the Upgrade
Zacks Investment Research
08 дек 2022 г. в 13:33
MaxCyte, Inc. (MXCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MaxCyte Is Poised For A Strong Rebound
Seeking Alpha
06 дек 2022 г. в 15:35
Overall bearish sentiment has increased the likelihood of finding bargains in healthcare stocks. MaxCyte, Inc.'s prospects are bright while the price currently looks attractive relative to the growth potential.
MaxCyte signs strategic platform licence with South Korean biotech
Proactive Investors
05 дек 2022 г. в 04:54
MaxCyte Inc (AIM:MXCT) has signed a strategic platform licence with a South Korean biotechnology company to enable cell and gene therapies for the treatment of rare intractable diseases. The cell engineering company said it will receive platform licensing fees and program-related revenue as part of the agreement.